1Stenvinkel P. Inflammation in end-stage renal failure: could it be treated? Nephrol Dial Transplant, 2002, 17(Supp 8): 33-38. 被引量：1
2Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation, 2003, 107(1): 87-92. 被引量：1
3Stenvinkel P, Diczfalusy U, Lindholm B, et al. Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased mortality in patients on renal replacement therapy. Nephrol Dial Transplant, 2004, 19: 972-976. 被引量：1
4Bayés B, Pastor C, Bonal J, et al. Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant, 2003, 18: 106-112. 被引量：1
5Boaz M, Mataz Z, Biro A, et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int, 1999, 56: 1078-1083. 被引量：1
6Handelman GJ, Walter MF, Adhikarla R, et al. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int, 2001, 59: 1960-1966. 被引量：1
7Witko-Sarsat V, Friedlander M, Khoa TN, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol, 1998, 161: 2524-2532. 被引量：1
8Mezzano D, Pais EO, Aranda E, et al. Inflammation, not hymerhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int, 2001, 60(5): 1844-1850. 被引量：1
9Nguyen-Khoa T, Massy ZA, De Bandt JP, et al. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant, 2001, 16: 335-340. 被引量：1
10Danielski M, Ikizler TA, McMonagle E, et al. Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. Am J Kidney Dis , 2003, 42: 286-294. 被引量：1
